Why Atossa Therapeutics, Inc.’s (ATOS) Stock Is Down 5.97%
As of Tuesday, May 05, Atossa Therapeutics, Inc.’s ATOS share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Commentary & Analysis
Why Atossa Therapeutics, Inc.’s (ATOS) Stock Is Down 5.02%
As of Tuesday, April 21, Atossa Therapeutics, Inc.’s ATOS share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Atossa Therapeutics, Inc.’s (ATOS) Stock Is Up 6.69%
As of Monday, April 20, Atossa Therapeutics, Inc.’s ATOS share price has surged by 6.69%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Atossa Therapeutics, Inc.’s (ATOS) Stock Is Up 1229.20%
As of Monday, February 02, Atossa Therapeutics, Inc.’s ATOS share price has surged by 1229.20%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Atossa Therapeutics, Inc.’s (ATOS) Stock Is Up 935.40%
As of Monday, February 02, Atossa Therapeutics, Inc.’s ATOS share price has surged by 935.40%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | ATOS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $23.7 | $232.8 | 11% |
|
| Shares Out (Mil) | 8.9 | 53.4 | 20% |
|
| Institutional Ownership | 97.3% | 92.9% | 73% |
|
| Float (Mil) | 9.9 | 41.2 | 19% |
|
| Beta | 1.27 | 0.96 | 74% |
|
| Avg Daily Volume (000s) | 90 | 490 | 35% |
|
| Price Change (52-week) |
(83.3%) | 48.2% | 8% |
|
| Growth | ATOS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (14.3%) | (10.1%) | 26% |
|
| EPS (5yr) | 32.9% | 15.8% | 84 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.0%) | (15.7%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.780) | ($3.560) | ($3.300) | |
| Month Ago EPS | ($1.100) | ($4.400) | ($4.380) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($1.100) | ($4.400) | ($4.380) | |
| Year/Year Chg | (18.2%) | (11.8%) | (167.2%) | |
| Financials | ATOS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($38) | ($44) | 19% |
|
| EPS (TTM) | ($4.343) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($36) | ($33) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($4) | $174 | 3% |
|
| Valuation | ATOS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.88 | 2.22 | 21% |
|
| P/E | na | 20.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ATOS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (77.9%) | (47.3%) | 7% |
|
| ROE | (89.2%) | (53.3%) | 10% |
|
| Liabilities to Assets | 16.9% | 29.4% | 11% |
|
| F-Score | 1 | 2 | 1% |
|
Atossa Therapeutics, Inc. did not pass any screens on 10/28/2026.
